DT120 not checked
Definium Therapeutics US, Inc. · MM120
FollowEvery change as it happens, and a Monday email
Trials
5 active
8 in total · 3 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)”In the company’s words, NCT06941844 on ClinicalTrials.gov
- Tested for
- Major Depressive Disorder (2 trials), Generalized Anxiety Disorder (2 trials)
- Main trialPhase 3
- “A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Emerge”In the company’s words, NCT06941844 on ClinicalTrials.gov
- Other names
- MM120 · lysergide tartrate · LSD D-Tartrate
Other drugs for Major Depressive Disorder
- SeltorexantJanssen Research & Development, LLC · Phase 3
- AzetukalnerXenon Pharmaceuticals Inc. · Phase 3
- LumateperoneIntra-Cellular Therapies, Inc. · Phase 3
- CYB003Cybin IRL Limited · Phase 3
- Mitizodone PhosphateSunshine Lake Pharma Co., Ltd. · Phase 2/3
- OsavampatorNeurocrine Biosciences · Phase 3
Coming up1
- Sep 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 20 May 2026 | A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge) | |
| Phase 3Active, not recruiting | 15 Jul 2026 | A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage) | |
| Phase 3Active, not recruiting | 13 Aug 2026 | A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) | |
| Phase 3Recruiting | Sep 2027 | A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) | |
| Phase 2Completed | 6 Oct 2023 | A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms | |
| Phase 2Completed | 6 Nov 2023 | Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial | |
| Phase 2Authorised | not given | Efficacy and safety of minidosing lysergic acid diethylamide (LSD) for chronic cluster headache: a randomized placebo-controlled study | |
| Phase 2Not authorised | not given | Microdosing with a serotonergic agent for ADHD and emotion regulation: biological factors explaining and predicting treatment response |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026